10:33 AM EDT, 06/05/2025 (MT Newswires) -- Harmony Biosciences ( HRMY ) said Thursday it and Lupin have resolved their legal fight alleging patent infringement that followed Lupin disclosing plans to make a generic version of Harmony's Wakix narcolepsy medication.

As part of the settlement agreement, Harmony will drop its lawsuit filed in federal court in Delaware and Lupin will be granted a license to launch a Wakix generic product no sooner than January 2030, or earlier depending on certain circumstances, Harmony said.

The decision follows the US Patent and Trademark Office last summer declining for a second time to take up a review of the patent protections underlying Wakix, which treats excessive sleepiness in the adults and youths with narcolepsy.

Harmony also has litigation pending against several other rivals seeking to market their own Wakix generics and said Thursday it remains committed to "vigorously protect" its patents.

Harmony shares were down 1% in recent trading.

Price: 34.96, Change: -0.20, Percent Change: -0.58